Debiopharm collaborates with the European Organisation for Research and Treatment of Cancer.
M2 EQUITYBITES-January 15, 2016-Debiopharm collaborates with the European Organisation for Research and Treatment of Cancer
(C)2016 M2 COMMUNICATIONS http://www.m2.com
Switzerland-based Debiopharm International is collaborating with the European Organisation for Research and Treatment of Cancer (EORTC).
It was reported yesterday that the collaboration is aimed at providing triptorelin pamoate 3.75 mg 1-month formulation for patients suffering from salivary cancer participating in a clinical study sponsored by the EORTC. Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone. Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate.
Salivary gland cancers are a rare and heterogeneous group of tumors. There is currently no standard of care for treating these cancers. The purpose of this study is to evaluate the efficacy and safety of chemotherapy versus androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptors-expressing salivary gland cancers.
This study will involve 152 patients at around 30 sites in 10 countries, Austria, Belgium, France, Germany, Greece, Hungary, Italy, the Netherlands, Portugal and the United Kingdom. The clinical study is likely to last until mid-2021.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jan 15, 2016|
|Previous Article:||Universal Insurance Holdings declares higher dividend of USD0.14 per share for quarter.|
|Next Article:||ThromboGenics enrols patients for ocriplasmin study.|